[1]Buechner J, Henriksen JR, Haug BH, et al. Inhibition of mir-21,which is up-regulated during MYCN knockdown-mediated differentiation, does not prevent differentiation of neuroblastoma cells [J]. Differentiation, 2011, 81(1):25-34.
[2]London WB, Castel V, Monclair T, et al. Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project [J]. J Clin Oncol, 2011, 29(24): 3286-3292.
[3]Pearson AD, Pinkerton CR, Lewis IJ, et al. High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial[J]. Lancet Oncol, 2008, 9(3): 247-256.
[4]Zage PE, Kletzel M, Murray K, et al. Outcomes of the POG 9340/9341/9342 trials for children with high-risk neuroblastoma: a report from the Children’s Oncology Group [J]. Pediatr Blood Cancer, 2008, 51(6):747-753.
[5]Coelho T, Adams D, Silva A, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis [J]. N Engl J Med, 2013, 369(9): 819-829.
[6]Hao J, Shi H, Zhao S, et al. Effects of SREBP-1 targeted RNAi on lipid droplet formation in HKC cells under stimulation of high glucose [J]. Chinese Pharmacological Bulletin, 2009, 25(3):371-377. (in Chinese)
郝军,石宏,赵松,等. 靶向抑制人SREBP-1基因对高糖刺激下人肾小管上皮细胞脂滴形成的影响[J]. 中国药理学通报,2009,25(3):371-377.
[7]Chen S, Ge X, Chen Y, et al. Advances with RNA interference in Alzheimer’s disease research [J]. Drug Des Devel Ther, 2013, 7(2):117-125.
[8]Voronkov A, Krauss S. Wnt/beta-catenin signaling and small molecule inhibitors[J]. Curr Pharm Des, 2012, 19(4): 634-664.
[9]Davar D, Beumer JH, Hamieh L, et al. Role of PARP inhibitors in cancer biology and therapy [J]. Curr Med Chem, 2012, 19(23): 3907-3921.
[10]Klapper W, Krams M, Qian W, et al. Telomerase activity in B-cell non-Hodgkin lymphomas is regulated by hTERT transcription and correlated with telomere-binding protein expression but uncoupled from proliferation[J]. Br J Cancer, 2003, 89(4): 713-719.
[11]Gelmini S, Poggesi M, Distante V, et al. Tankyrase, a positive regulator of telomere elongation, is over expressed in human breast cancer [J]. Cancer Lett, 2004, 216(1):81-87.
[12]Gelmini S, Poggesi M, Pinzani P, et al. Distribution of tankyrase-1 mRNA expression in colon cancer and its prospective correlation with progression stage [J]. Oncol Rep, 2006,16 (6):1261-1266.
[13]Gelmini S, Quattrone S, Malentacchi F, et al. Tankyrase-1 mRNA expression in bladder cancer and paired urine sediment: preliminary experience [J]. Clin Chem Lab Med, 2007, 45(7):862-866.
[14]Shervington A, Patel R, Lu C, et al. Telomerase subunits expression variation between biopsy samples and cell lines derived from malignant glioma [J]. Brain Res, 2007, 1134(1):45-52.
[15]Tang ChZh, Zhang WX, Gao DW, et al. Changes of the ultrastructure of colon mucosa after partial hepatectomy in rats [J]. Acta Anatomica Sinica, 2012,43(4):545-550. (in Chinese)
唐超智,张文学,高道文,等. 部分肝切除后大鼠结肠黏膜层超微结构的变化[J]. 解剖学报,2012,43(4):545-550.
[16]Tan ChY. The progresses of diagnosis and treatment for neuroblastoma[J]. The Journal of Chinese Birth Health and Heredity, 2011,19(1):132-134. (in Chinese)
谭春英. 神经母细胞瘤的诊治进展[J]. 中国优生与遗传杂志,2011,19(1):132-134.
[17]Smith MA, Seibeil NL, Altekruse SF, et al. Outcomes for children and adolescents with cancer: challenges for the twenty-first century [J]. J Clin Oncol, 2010, 28 (15): 2625-2634.
[18]Muramatsu Y, Ohishi T, Sakamoto M, et al. Cross-species difference in telomeric function of tankyrase 1[J]. Cancer Sci, 2007, 98(6): 850-857.
[19]Huang SM, Mishina YM, Liu S, et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt sianaling[J]. Nature, 2009, 461(7264): 614-620.
[20]Busch AM, Johnson KC, Stan RV, et al. Evidence for tankyrases as antineoplastic targets in lung cancer[J]. BMC Cancer, 2013, 13(4):211.
[21]Bao R, Christova T, Song S, et al. Inhibition of tankyrases induces Axin stabilization and blocks Wnt signalling in breast cancer cells [J]. PLoS One, 2012, 7(11): e48670.
[22]Waaler J, Machon O, Tumova L, et al. A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice [J]. Cancer Res, 2012, 72(11): 2822-2832.
[23]Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Coenorhabditis elegans [J]. Nature, 1998, 391(6669): 806-811.
[24]Fish RJ, Kruithof EK. Short-term cytotoxic effects and long-term instability of RNAi delivered using lentiviral vectors [J]. BMC Mol Biol, 2004, 5(8): 9.
[25]Yang W, Kang J, Wang X, et al. Comparison between lentivirus and plasmid as shRNA vector targeting RhoA gene of ovary cancer cell line HO8910[J]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, 2013, 29(5): 473-476, 480.
[26]Zhao X, Zhu DM, Gan WJ, et al. Lentivirus-mediated shRNA interference targeting vascular endothelial growth factor inhibits angiogenesis and progression of human pancreatic carcinoma [J]. Oncol Rep, 2013, 29(3):1019-1026.
[27]Pang WJ, Xiong Y, Zhang Z, et al. Lentivirus-mediated Sirt1 shRNA and resveratrol independently induce porcine preadipocyte apoptosis by canonical apoptotic pathway [J]. Mol Biol Rep, 2013, 40(1):129-139.
[28]Clevers H. Wnt/beta-catenin signaling in development and disease [J]. Cell, 2005, 127(3): 469-680.
|